United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Washington will pay $1.95 billion to the companies for 100 million doses of their SARS-CoV-2 vaccine -- if it passes muster.

Pfizer and BioNTech Ink Deal with U.S. Government for Big Coronavirus Vaccine Purchase

Q2 earnings season really hits the accelerator today; it's the single-biggest day of earnings reports for the quarter so far.

Big Day for Q2 Earnings, U.S. Spends $1.95B on Pfizer Drug

Pfizer Inc. (NYSE: PFE) and BioNTech S.E.

Pfizer and BioNTech Set to Receive a Sweet Payoff for COVID-19 Vaccines

The vaccine could be available as early as October.

Pfizer Gets $1.95 Billion U.S. Deal For 100 Million Doses Of Planned Covid-19 Vaccine

The company just released encouraging early data about its coronavirus vaccine program.

Is Now a Good Time to Buy Pfizer Stock?

Pfizer and BioNTech scored a deal with the U.S. government Wednesday for up to 600 million doses of their coronavirus vaccine.

Pfizer, BioNTech Score $2 Billion Deal For Coronavirus Vaccine In U.S.

Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) have announced the award of another contract to supply their jointly-developed coronavirus vaccine candidate that's currently in Phase 1/2 development.

Pfizer, BioNTech To Supply US Government 600M Doses Of Coronavirus Vaccine

The feds placed a $2 billion order for 100 million doses of Pfizer’s potential coronavirus vaccine under the Trump administration’s push to have a shot ready by next year. Americans would receive Pfizer’s shots for free under the deal announced Wednesday — assuming the vaccine it’s developing with the German biotech firm BioNTech wins federal.

Feds order 100 million doses of Pfizer’s COVID-19 vaccine for $2 billion

AstraZeneca

Johnson & Johnson

Moderna

Novavax

Vaxart

The U.S. government is pouring money into coronavirus vaccine development, and a handful of companies are cashing in.

Everything You Need to Know About Operation Warp Speed's Coronavirus Vaccine Accelerator

BioNTech BNTX, +3.85% and Pfizer Inc. PFE, +0.52% said they will receive $1.95 billion from the U.S.

BioNTech, Pfizer shares gain on U.S. funding for coronavirus vaccine doses

The vaccine is being jointly developed by German biotech firm BioNTech and U.S.-based Pfizer.

U.S. government taps Pfizer to produce millions of doses of coronavirus vaccine

New research could mean the market opportunity for COVID-19 vaccines might be bigger than expected. Or maybe not.

Could These Findings Dramatically Change the Opportunities for COVID-19 Vaccine Stocks?

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?

Merck

Drug company executives insisted Tuesday they aren’t cutting corners in fast-tracking development of potential vaccines to prevent infection of the coronavirus.

Pharma executives promise Congress they aren't cutting corners in fast tracking coronavirus vaccine

Attaining a new fast-track designation for a vaccine is often beneficial for a company’s shareholders in the short term, but it also implies intensified organizational and scientific challenges.

What Does It Mean for Investors When a Coronavirus Vaccine Is "Fast-Tracked"?

Abbott Labs

Here's why Abbott Laboratories and Pfizer are great picks for long-term investors.

Have $2,000? Consider Buying These 2 Top Coronavirus Stocks

Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports second-quarter results.

Can Pfizer (PFE) Deliver a Beat in Coronavirus-Hit Q2 Earnings?

The news comes on the same day that the two companies announced promising clinical trial results of their mRNA-based candidate.

U.K. Secures 30 Million Doses of Coronavirus Vaccine Candidate From Pfizer and BioNTech

The data shows more positives about Pfizer’s (NYSE: PFE) coronavirus vaccine candidate and remains in-line with its German partner BioNTech’s (NASDAQ: BNTX) study, according to Cantor Fitzgerald Securities.

4 Takeaways On Pfizer's Latest Coronavirus Data

Pfizer and BioNTech stocks rose Monday after the companies agreed to supply 30 million doses of their coronavirus vaccine to the U.K. AstraZeneca dipped on its early-stage vaccine test.

Pfizer, BioNTech Rise On U.K. Supply Deal For Coronavirus Vaccine

The race to develop a coronavirus vaccine is heating up.

Coronavirus Vaccine Program From Pfizer and BioNTech Reports Preliminary Success

BioNTech SE (NASDAQ: BNTX) and Pfizer Inc. (NYSE: PFE) are leading the pack of COVID-19 vaccine stocks as this collaboration came out with more positive news regarding their ongoing German Phase 1/2 study.

Pfizer and BioNTech Make Another Big Step for COVID-19 Vaccine

German biotech firm BioNTech and U.S. drugmaker Pfizer on Monday reported additional data from their experimental coronavirus vaccine that showed the vaccine was safe and induced an immune response in patients.

Additional data on Pfizer and BioNTech's potential coronavirus vaccine shows promise

Shares of BioNTech BNTX, +12.36% and Pfizer Inc. PFE, +1.82% both jumped in premarket trading on Monday after the companies said their experimental COVID-19 vaccine produced a T-cell response in people participating in a Phase 1/2 clinical trial in Germany.

BioNTech, Pfizer shares rally on preliminary data showing T-cell response from coronavirus vaccine candidate

Coronavirus vaccine partners Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) had incremental positive tidings concerning their mRNA vaccine candidate to combat SARS-CoV-2, the virus that causes COVID-19, sending shares of both companies sharply higher.

News for Pfizer Stock (PFE)